|
Feb 13
|
Royalty Pharma pays $250m for rights to Biogen’s lupus drug
|
|
Feb 13
|
Biogen Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 13
|
Biogen Inc (BIIB) Q4 2024 Earnings Call Highlights: Strong EPS Growth Amid Revenue Challenges
|
|
Feb 13
|
Q4 2024 Biogen Inc Earnings Call
|
|
Feb 12
|
Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat
|
|
Feb 12
|
Biogen (BIIB) Q4 2024 Earnings Call Transcript
|
|
Feb 12
|
Vertiv, Biogen, Super Micro Computer: Market Minute
|
|
Feb 12
|
Biogen Expects Decline in 2025 Revenue, Reports Fourth-Quarter Beat
|
|
Feb 12
|
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
|
|
Feb 12
|
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
|
|
Feb 12
|
Q4 2024 SAGE Therapeutics Inc Earnings Call
|
|
Feb 12
|
Biogen expects 2025 profit decline despite strong Q4
|
|
Feb 12
|
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
|
|
Feb 12
|
Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Feb 12
|
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
|
|
Jan 4
|
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
|
|
Jan 2
|
Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges
|
|
Jan 1
|
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
|
|
Jan 1
|
The 5 worst performing stocks on the Nasdaq 100 in 2024
|
|
Dec 11
|
Biogen reinstated with a Neutral at BofA
|